Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ainos, Inc. stock logo
AIMD
Ainos
$3.19
$2.84
$2.00
$5.00
$13.37M2.1394,523 shs6,749 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.40
-0.4%
$1.43
$0.94
$2.55
$22.74M0.88237,766 shs37,590 shs
NVLNF
Novelion Therapeutics
$0.70
-1.2%
$0.70
$0.51
$1.00
$13.77M2.15261,364 shs26,900 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ainos, Inc. stock logo
AIMD
Ainos
+3.24%0.00%+3.20%+22.69%-23.13%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
+0.72%+0.72%-7.89%+30.84%-20.00%
NVLNF
Novelion Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ainos, Inc. stock logo
AIMD
Ainos
0.7322 of 5 stars
0.04.00.00.00.61.70.6
NanoViricides, Inc. stock logo
NNVC
NanoViricides
1.1088 of 5 stars
0.05.00.00.03.90.00.0
NVLNF
Novelion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ainos, Inc. stock logo
AIMD
Ainos
0.00
N/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00
N/AN/AN/A
NVLNF
Novelion Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ainos, Inc. stock logo
AIMD
Ainos
$106.21K125.91N/AN/A$5.51 per share0.58
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
NVLNF
Novelion Therapeutics
$130.43M0.11N/AN/A($4.69) per share-0.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ainos, Inc. stock logo
AIMD
Ainos
-$14.86M-$6.45N/AN/AN/A-88.07%-48.60%8/4/2025 (Estimated)
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.70N/AN/AN/A-87.90%-78.69%N/A
NVLNF
Novelion Therapeutics
-$108.33MN/A0.00N/AN/AN/AN/AN/A

Latest NVLNF, AIMD, and NNVC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Ainos, Inc. stock logo
AIMD
Ainos
N/A-$1.05N/A-$0.21N/A$0.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ainos, Inc. stock logo
AIMD
Ainos
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
NVLNF
Novelion Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ainos, Inc. stock logo
AIMD
Ainos
0.84
2.00
1.91
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47
NVLNF
Novelion Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Ainos, Inc. stock logo
AIMD
Ainos
N/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%
NVLNF
Novelion Therapeutics
48.64%

Insider Ownership

CompanyInsider Ownership
Ainos, Inc. stock logo
AIMD
Ainos
10.39%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
4.60%
NVLNF
Novelion Therapeutics
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ainos, Inc. stock logo
AIMD
Ainos
404.19 million3.76 millionNot Optionable
NanoViricides, Inc. stock logo
NNVC
NanoViricides
2016.07 million14.92 millionOptionable
NVLNF
Novelion Therapeutics
10919.62 millionN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ainos stock logo

Ainos NASDAQ:AIMD

$3.19 0.00 (0.00%)
As of 09:59 AM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.40 -0.01 (-0.36%)
As of 10:26 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Novelion Therapeutics OTCMKTS:NVLNF

$0.70 -0.01 (-1.20%)
As of 01/16/2020

Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.